Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years
Condition: Influenza Interventions: Biological: OVX836; Biological: Quadrivalent seasonal influenza vaccine (Influvac TetraTM) Sponsors: Osivax S.A.S; Centre for vaccinology (CEVAC), University of Ghent Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials